Doxorubicin

1266 Words3 Pages

Introduction
Liposomes are vesicles consisting of one or more phospholipids bilayers encasing an aqueous compartment as seen in Figure 1 (1-3). By allowing encapsulation of drugs, DNA or proteins within the compartment, it can facilitate drug movement to particular targets while eliciting varying pharmacokinetic characteristics that enhances the therapeutic effect of delivered contents (2, 3). Due to their ease of preparation, versatility and biologically non-toxic nature, liposomes have been a focus of medical research in hopes of improving therapeutic outcomes for drugs with unfavourable pharmacokinetics (1).
One such aforementioned drug is Doxorubicin, a widely used chemotherapeutic agent used in the treatment of cancer conditions such …show more content…

Doxorubicin is an anti-cancer agent which should only be affecting cancerous tissues but conventional doxorubicin lacks the ability to differentiate normal from cancerous cells and affects all tissues based on its systemic circulation (2, 4). Liposomal doxorubicin as nanocarriers size within the nano to micro ranges being larger than conventional small drug molecules allows manipulation of a phenomenon called the enhanced penetration and retention (EPR) (2, 4). EPR is a passive targeting effect in which the molecule takes advantage of tumour pathophysiological characteristics that extravasate macromolecules into cancerous tissues while depleting lymphatic drainages to prevent macromolecule clearance as seen Figure 5 (4).
Furthermore, current marketed liposomal doxorubicin features pegylation, in which liposomal doxorubicin is pegylated or otherwise known as coated with polyethylene glycol (13). The polyethylene glycol impedes detection by the mononuclear phagocyte system allowing it extended circulation periods without elimination (7, 13). Increases in circulation period compound aid to liposomes EPR effect in accumulating within cancerous …show more content…

Blanco E, Ferrari M. Emerging nanotherapeutic strategies in breast cancer. Breast (Edinburgh, Scotland). 2014 Feb;23(1):10-8. PubMed PMID: 24215984. Epub 2013/11/13. eng.
8. Handbook AM, Buckley N, Australia PSo. Australian Medicines Handbook 2014: Australian Medicines Handbook Pty. Limited; 2014.
9. Lasic DD, Martin FJ. Stealth Liposomes: Taylor & Francis; 1995.
10. Bangham AD, Standish MM, Watkins JC. Diffusion of univalent ions across the lamellae of swollen phospholipids. Journal of Molecular Biology. 1965 8//;13(1):238-IN27.
11. Haran G, Cohen R, Bar LK, Barenholz Y. Transmembrane ammonium sulfate gradients in liposomes produce efficient and stable entrapment of amphipathic weak bases. Biochimica et Biophysica Acta (BBA) - Biomembranes. 1993 9/19/;1151(2):201-15.
12. Accardo A, Aloj L, Aurilio M, Morelli G, Tesauro D. Receptor binding peptides for target-selective delivery of nanoparticles encapsulated drugs. International journal of nanomedicine. 2014;9:1537-57. PubMed PMID: 24741304. Pubmed Central PMCID: PMC3970945. Epub 2014/04/18. eng.
13. Allen TM, Hansen C, Martin F, Redemann C, Yau-Young A. Liposomes containing synthetic lipid derivatives of poly(ethylene glycol) show prolonged circulation half-lives in vivo. Biochimica et Biophysica Acta (BBA) - Biomembranes. 1991

Open Document